Zevra Therapeutics Updates Executive Compensation Arrangements
Ticker: ZVRA · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-compensation, corporate-governance, 8-K
TL;DR
**Zevra Therapeutics just updated how it pays its top brass, watch for details on new incentives.**
AI Summary
Zevra Therapeutics, Inc. filed an 8-K on January 23, 2024, to report changes in its executive compensation arrangements. This filing, under Item 5.02, indicates that the company is updating how it compensates certain officers, which could include new equity grants, salary adjustments, or bonus structures. For investors, this matters because executive compensation can influence management's incentives and the company's financial health, potentially impacting stock performance.
Why It Matters
Changes in executive compensation can signal shifts in company strategy or performance expectations, directly affecting management's motivation and potentially the company's bottom line.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of changes in executive compensation, which typically carries a low direct risk unless the changes are unusually large or controversial.
Analyst Insight
Investors should monitor future filings or company announcements for specific details on the compensatory arrangements, as these could impact executive retention and motivation, which are key to long-term company performance.
Key Numbers
- $0.0001 — Par Value per Share (The nominal value of each share of Zevra Therapeutics' Common Stock.)
Key Players & Entities
- Zevra Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 23, 2024 (date) — date of earliest event reported
- 001-36913 (other) — Commission File Number
- 20-5894398 (other) — IRS Employer Identification No.
- 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 (other) — Address of Principal Executive Offices
- (321) 939-3416 (other) — Registrant's Telephone Number
- ZVRA (other) — Trading Symbol for Common Stock
- $0.0001 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- Zevra Therapeutics will provide more specific details on the executive compensation changes in future filings or press releases. (Zevra Therapeutics, Inc.) — medium confidence, target: Q1 2024
FAQ
What is the purpose of Zevra Therapeutics, Inc.'s 8-K filing dated January 23, 2024?
The 8-K filing by Zevra Therapeutics, Inc. on January 23, 2024, is to report information under Item 5.02, specifically regarding 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
What is the trading symbol and par value of Zevra Therapeutics, Inc.'s common stock?
The trading symbol for Zevra Therapeutics, Inc.'s common stock is ZVRA, and its par value is $0.0001 per share.
Where are Zevra Therapeutics, Inc.'s principal executive offices located?
Zevra Therapeutics, Inc.'s principal executive offices are located at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.
What is the Commission File Number for Zevra Therapeutics, Inc.?
The Commission File Number for Zevra Therapeutics, Inc. is 001-36913.
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 23, 2024.
Filing Stats: 1,011 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-01-23 07:37:15
Key Financial Figures
- $0.0001 — ch registered Common Stock , par value $0.0001 per share ZVRA The Nasdaq Stock Mark
- $40,000 — Shih will be entitled to receive a $40,000 annual retainer for his service as
Filing Documents
- zvra20240112_8k.htm (8-K) — 32KB
- 0001437749-24-001909.txt ( ) — 166KB
- zvra-20240123.xsd (EX-101.SCH) — 3KB
- zvra-20240123_def.xml (EX-101.DEF) — 12KB
- zvra-20240123_lab.xml (EX-101.LAB) — 15KB
- zvra-20240123_pre.xml (EX-101.PRE) — 12KB
- zvra20240112_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       Zevra Therapeutics, Inc .         Date: January 23, 2024   By: /s/ R. LaDuane Clifton       R. LaDuane Clifton, CPA       Chief Financial Officer, Secretary and Treasurer